Novo Nordisk’s GLP-1 Drugs Continue to Boost Sales
Novo Nordisk, a global healthcare company, has seen significant growth driven by its GLP-1 drug portfolio, which includes well-known brands like Ozempic, Rybelsus, and Wegovy. These drugs have been pivotal in managing diabetes and obesity, contributing to the company’s robust financial performance in recent quarters. Financial Performance Highlights In the first quarter of 2024, Novo…